Steward M W, Partidos C D, D'Mello F, Howard C R
Department of Clinical Sciences, London School of Hygiene and Tropical Medicine, UK.
Vaccine. 1993 Nov;11(14):1405-14. doi: 10.1016/0264-410x(93)90169-x.
The amino acid sequence 139-147 from hepatitis B surface antigen (HBsAg) has previously been shown to represent a B-cell epitope with potential as a component of a synthetic peptide vaccine against hepatitis B. In this paper, two regions of HBsAg which act as T-cell epitopes in inbred mice have been identified (residues 23-34 and residues 160-171). The ability of synthetic peptides representing these epitopes to provide help for the production of antibody against the 139-147 epitope has been assessed following their co-linear synthesis with the B-cell epitope and following co-immunization of the peptides in an uncoupled form. Both these strategies result in the induction of anti-peptide antibodies which specifically react with recombinant HBsAg. The results presented give further support to the concept that synthetic peptides representing appropriately chosen B- and T-cell epitopes from HBsAg could form the basis of a synthetic vaccine against hepatitis B.
先前已证明,来自乙肝表面抗原(HBsAg)的139 - 147氨基酸序列代表一种B细胞表位,有潜力作为抗乙肝合成肽疫苗的一个组成部分。在本文中,已鉴定出乙肝表面抗原在近交系小鼠中作为T细胞表位的两个区域(23 - 34位氨基酸残基和160 - 171位氨基酸残基)。在将代表这些表位的合成肽与B细胞表位进行共线性合成以及以非偶联形式对这些肽进行共免疫之后,评估了这些合成肽为针对139 - 147表位产生抗体提供辅助的能力。这两种策略均导致诱导出能与重组乙肝表面抗原特异性反应的抗肽抗体。所呈现的结果进一步支持了这样一种概念,即代表从乙肝表面抗原中适当选择的B细胞和T细胞表位的合成肽可构成抗乙肝合成疫苗的基础。